Dr. John T. Hamm, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 246
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
KY license 22818
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Norton Hospitals, Inc Louisville, KY
- Norton Clark Hospital Jeffersonville, IN
Medical groups
- Norton Hospitals, Inc (137 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 246
- Services billed
- 1,463
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 570 | 210 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 181 | 52 |
| Established patient office or other outpatient visit, 40-54 minutes | 94 | 54 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 42 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Louisville, KY | 138 |
| Promethazine Hcl Other prescribers in Louisville, KY | 93 |
| Dexamethasone Other prescribers in Louisville, KY | 70 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Louisville, KY | 67 |
| Pantoprazole Sodium Other prescribers in Louisville, KY | 65 |
| Levothyroxine Sodium Other prescribers in Louisville, KY | 64 |
| Anastrozole Other prescribers in Louisville, KY | 45 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Louisville, KY | 44 |
| Ibrance (palbociclib) | 40 |
| Ciprofloxacin Hcl Other prescribers in Louisville, KY | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $264 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $135 |
|---|---|
| BioNTech SE | $112 |
| Daiichi Sankyo Inc. | $17.73 |
| Food and Beverage | $264 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 13 companies. The companies reported $612,068 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen Inc. - BNT317-01
BioNTech SE - Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie Inc. · Recruiting · NCT05005403 - Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi US Services Inc. · Terminated · NCT04717375 - BNT116-01
BioNTech SE - A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment Wi…
Genmab A/s - A lowinterventional study to assess GDF15 levels in adult participants with cachexia and malignant solid tumors
Pfizer Inc. - First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors.
Genmab U.S., Inc. - A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
AstraZeneca Pharmaceuticals LP - An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or meta…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.